SCHEMBL5099703

SCHEMBL5099703

Cc1ccc(S(=O)(=O)OC(C)C(=O)Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.41
KMT2A Q03164 6/20 0.39
MEN1 O00255 4/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
MMP1 P03956 2/20 0.39
MMP2 P08253 2/20 0.39
MMP9 P14780 2/20 0.39
MMP13 P45452 2/20 0.39
MMP8 P22894 1/20 0.39
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
POLB P06746 2/20 0.39
HTT P42858 1/20 0.39
NOD2 Q9HC29 1/20 0.39
CA12 O43570 1/20 0.38
CA3 P07451 1/20 0.38
CA6 P23280 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5099695 1.00 GAA (0.41) GAAKMT2AMEN1CA1CA2
SCHEMBL9594005 1.00 GAA (0.41) GAAKMT2AMEN1CA1CA2
SCHEMBL9522957 0.86 GAA (0.43) GAAKMT2AMEN1CA1CA2
SCHEMBL9592203 0.84 LMNA (0.41) KMT2AMEN1ALDH1A1LMNAHTT
SCHEMBL9593680 0.84 LMNA (0.41) KMT2AMEN1ALDH1A1LMNAHTT
SCHEMBL10964785 0.84 LMNA (0.41) KMT2AMEN1ALDH1A1LMNAHTT
SCHEMBL1869422 0.84 MMP9 (0.45) GAAKMT2AMEN1CA1CA2
SCHEMBL10806036 0.84 GAA (0.42) GAAKMT2AMEN1CA1CA2
SCHEMBL4372757 0.84 MMP9 (0.45) GAAKMT2AMEN1CA1CA2
SCHEMBL2325722 0.84 MMP9 (0.45) GAAKMT2AMEN1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368580-B2 Method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof LES LABORATORIES SERVIER (FR) 2008-05-06 US disclosed
US-7358372-B2 Method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof LES LABORATORIES SERVIER (FR) 2008-04-15 US disclosed
US-20060189813-A1 Novel method for the synthesis of perinidopril and the pharmaceutically acceptable salts thereof LES LABORATOIRES SERVIER (FR) 2006-08-24 US disclosed
US-20060183920-A1 Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof LES LABORATOIRES SERVIER (FR) 2006-08-17 US disclosed
EP-0595345-B1 Process for producing alanylglutamine KYOWA HAKKO KOGYO KK (JP) 2000-01-12 EP disclosed
US-5550283-A Process for producing alanylglutamine KYOWA HAKKO KOGYO CO., LTD. (JP) 1996-08-27 US disclosed
US-5380934-A Process for producing alanylgutamine KYOWA HAKKO KOGYO CO., LTD. (JP) 1995-01-10 US disclosed
EP-0595345-A1 Process for producing alanylglutamine KYOWA HAKKO KOGYO CO., LTD. (JP) 1994-05-04 EP disclosed
US-4699949-A Hardening of acid-hardenable compositions containing a blocked hardening catalyst, using heat CIBA-GEIGY CORPORATION (US) 1987-10-13 US disclosed
EP-0132225-B1 CURING OF ACID-CURABLE COMPOSITIONS CONTAINING A BLOCKED CATALYST WITH THE AID OF HEAT CIBA-GEIGY AG (CH) 1987-08-19 EP disclosed
US-4596594-A For removal of unwanted vegetation BAYER AKTIENGESELLSCHAFT (DE) 1986-06-24 US disclosed
US-4447259-A 2-(Substituted phenoxy)propionic acid derivatives and their uses for herbicidal purposes HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) 1984-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183920-A1 Novel method for the synthesis of perindopril and the pharmaceutically acceptable salts thereof ACE, QDPR, REN GAA 947/4885KMT2A 3052/4885MEN1 4611/4885
US-20060189813-A1 Novel method for the synthesis of perinidopril and the pharmaceutically acceptable salts thereof QDPR, ACE, REN GAA 766/4885KMT2A 2847/4885MEN1 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.